Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY 3670549 · 1 trial · 1 indication
AF = atrial fibrillation ; SR = sinus rhythm ; SoC = Standard of Care;
| Arm | Type | Description |
|---|---|---|
| BAY 3670549 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BAY 3670549 | DRUG | intravenous (IV) treatment |
| Placebo | OTHER | intravenous (IV) treatment |
Inclusion Criteria: * Participant must be 18 to 85 years of age inclusive, at the time of signing the informed consent. * Participant is hemodynamically stable and does not require emergency cardioversion, as determined by the investigator. * Participant has a current episode of atrial fibrillation...
Top 5 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 3 | PHASE3 | REGN7508, REGN9933 |
| Johnson & Johnson | JNJ | 14 | PHASE3 | Milvexian |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Abelacimab, PKN605 |
| Milestone Pharmaceuticals, Inc. | MIST | 1 | PHASE3 | Etripamil |
| Bayer | BAYRY | 1 | PHASE2 | BAY 3670549 |
BAY 3670549 is an investigational small molecule being studied for the treatment of atrial fibrillation, a common heart rhythm disorder. It is in Phase 2 clinical development and is not yet approved for any use. Bayer AG is evaluating it in patients with atrial fibrillation.
BAY 3670549 is being developed by Bayer AG, which trades on the OTC market under the ticker BAYRY. Bayer is the sponsor of the clinical program evaluating the compound in atrial fibrillation.
BAY 3670549 is in Phase 2 clinical development. It is an investigational small molecule and has not been approved by the FDA or any other regulatory agency. One Phase 2 trial is currently recruiting participants.
BAY 3670549 is being studied in the Phase 2 trial NCT07625215, titled A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation. The trial is recruiting and plans to enroll 360 participants across the United States, Belgium, Bulgaria, Germany, Hungary, Italy, the Netherlands, and Poland.
The Phase 2 trial NCT07625215 is a randomized, double-blind, placebo-controlled study of BAY 3670549 in patients with atrial fibrillation. It plans to enroll 360 participants aged 18 years and older, and it does not select patients based on a biomarker. The trial is currently recruiting.